PubMed Health⌕ Search

Biomedical subjects

E Katongole-Mbidde

Publications and source records attributed to E Katongole-Mbidde.

10 recordsLinked to original sources
PubMed1989

Diagnostic implications of genital Kaposi's sarcoma.

Genital Kaposi's sarcoma (KS) before the AIDS epidemic was rarely seen in Uganda although a case was seen in 1973, 1982, 1983 and 1985. Eight cases were seen in 1986 and another 17 cases have been documented since the beginning of 1987. Of the 29 patients, 23 were males, 6 females (M:F = 3.8:1); median age 29 years (range 7-70 years). All except 8 males were under 40 years. Six patients had pure nodular disease, while the rest had mixed clinical type. The external genitalia was involved in nodular disease in 15 patients, 12 had infiltrative disease and 6 had ulcerative disease. Florid and plaque were seen in one case each. Mixed cellularity was typed in 13 patients. 19(70.4%) were positive for HIV serology (ELISA Wellcome kit) of whom 13(61.9%) were males. All females were positive. The patient who presented in 1973 remains alive and disease free 13.5 years making it unlikely that he had AIDS. It appears therefore that genital KS is a feature of HIV associated KS and this mode of presentation is new in Uganda.

Adolescent↗
PubMed1978

Childhood Hodgkin's disease in Uganda: a ten year experience.

Between 1967 and 1977, 48 patients with Hodgkin's disease under 16-years-old were treated with MOPP chemotherapy alone at the Uganda Cancer Institute because radiotherapy facilities are not available. Thirty-eight percent had early stage disease (stages I-IIIA). Prolonged first remissions were achieved in 74% of 42 complete responders. Of 11 patients who relapsed, 5 had prolonged second remissions induced by MOPP. Three patients were lost to follow-up and 15 of the remaining 45 died: 12 of these from progressive Hodgkin's disease, 2 from unrelated causes and 1 from Burkitt's lymphoma after 4 months remission from Hodgkin's disease. Acturial survival for all patients is 67% (75% for stages I-IIIA and 60% for stages IIIB-IV). Treatment complications included Herpes zoster and gynaecomastia. The latter is probably related to gonadal dysfunction. All stages of childhood Hodgkin's disease can be successfully managed with MOPP chemotherapy alone.

Adolescent↗
PubMed1977

Cerebrospinal irradiation of Burkitt's lymphoma. Failure in preventing central nervous system relapse.

Twenty-two patients with Burkitt's lymphoma in complete remission induced by either cyclophosphamide or a combination of cyclophosphamide, oncovin and methotrexate were randomized to receive or not to receive prophylactic cerebrospinal irradiation. Six of 11 irradiated patients relapsed with tumour of the central nervous system as compared to 4 of 11 controls. Relapse frequency appeared to be related to stage of disease on admission. It is concluded that irradiation does not prevent relapse.

Brain↗
PubMed1976

Treatment of Burkitt's lymphoma: randomized clinical trial of single-agent versus combination chemotherapy.

A randomized clinical trial designed to compare the effectiveness of cytoxan (CTX) alone versus a combination consisting of CTX, vincristine (Oncovin) and methotrexate (COM) in the treatment of Burkitt's lymphoma (BL) was carried out. Nineteen patients were selected at random to receive CTX alone while 21 received COM. The two treatment regimens were equally effective in inducing remissions, and complete response rates of 83.3% and 84.3% were observed for CTX- and COM-treated patients, respectively. The relapse frequencies were also equal but the pattern of relapse was clearly different. Seven out of 8 (87.5%) in the CTX group relapsed with systemic and central nervous system (CNS) tumor, while 8 out of 10 (80%) in the COM group relapsed with CNS disease only. This difference is highly significant p = 0.008. The remission durations and survival to date are the same.

Burkitt Lymphoma↗
PubMed1975

Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication.

In a Phase II clinical trial, 14 patients with histologically proven primary hepatocellular carcinoma were treated with adriamycin administered intravenously at a dose of 75 mg/m2 every 3 weeks. All 11 evaluable patients responded with 3 exhibiting complete tumor regression after two, three, and five courses of adriamycin respectively. The remission durations for these 3 were 3, 6, and 7 months, and their survivals were 8, 9, and 13 months, respectively. The median survival of the evaluable patients is 8 months (range 1-13 months). The side effects encountered included myelosuppression, anorexia, nausea, vomiting, and alopecia. Adriamycin seems to be an effective agent in hepatocellular carcinoma. Further trials are underway to test its true efficacy both singly and in combination with other drugs in the management of this tumor.

Adult↗